Fmoc-5-氨基-3-氧杂戊酸 | 260367-12-2

• 物质功能分类: 生物化工 - 生化试剂 - 氨基酸
• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 中文名称: Fmoc-5-氨基-3-氧杂戊酸
• 中文别名: FMOC-5-氨基-3-氧戊酸；N-芴甲氧羰基-5-氨基-3-氧杂戊酸；FMOC- 5-氨基-3-氧戊酸
• 英文名称: 2-(2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)ethoxy)acetic acid
• 英文别名: 2-[2-(9H-fluoren-9-ylmethoxycarbonylamino)ethoxy]acetic acid
• CAS: 260367-12-2
• 化学式: C₁₉H₁₉NO₅
• 分子量: 341.364
• InChiKey: LBVXPUINIMIGAU-UHFFFAOYSA-N

物化性质

• 沸点：
  602.6±40.0 °C(Predicted)
• 密度：
  1.287±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  25
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  84.9
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 海关编码：
  2924299090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 5-(9-Fluorenylmethyloxycarbonyl-amino)-3-oxapentanoic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 5-(9-Fluorenylmethyloxycarbonyl-amino)-3-oxapentanoic acid
CAS number: 260367-12-2

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C19H19NO5
Molecular weight: 341.4

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

生物活性

Fmoc-NH-PEG1-CH2COOH 是一种可降解的 ADC 链接剂，用于抗体药物偶联物（ADC）合成。同时，它也是一种基于聚乙二醇 (PEG) 的 PROTAC 链接剂，可用于 PROTAC 合成。

靶点

特性	说明
可切链
烷基/醚
聚乙二醇 (PEG)

体外研究

ADCs 由抗体组成，通过 ADC 链接剂连接至一种细胞毒性药物。PROTACs 包含两个不同的配体，通过链接剂连接在一起；一个用于 E3 泛素连接酶，另一个用于靶蛋白。PROTACs 利用细胞内泛素-蛋白酶体系统选择性降解目标蛋白质。

反应信息

• 作为反应物：
  描述：

  Fmoc-5-氨基-3-氧杂戊酸 在 氯化亚砜 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 0.5h， 生成 5'-(2-(2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)ethoxy)acetamido)-[2,2'-bipyridine]-5-carboxylic acid
  参考文献：
  名称：

  立体选择性形成手性金属肽

  摘要：

  打在我们手中：非手性联吡啶氨基酸芴5-氨基-3- oxapentanoic酸羰基（Fmoc-O1PenBpy-OH）已被用于metallopeptides的固相合成。圆二色性，分子模型和NMR光谱研究表明，所得金属配合物在水溶液中的手性是确定的，因此可以通过两个配位的O1PenBpy残基之间的环中一个脯氨酸残基的立体化学来控制。

  DOI：

  10.1002/chem.201201036
• 作为产物：
  描述：

  (2-氨基乙氧基)乙酸 、 9-芴甲基-N-琥珀酰亚胺基碳酸酯 在 sodium carbonate 作用下， 以 1,4-二氧六环 、 水 为溶剂， 以13.2 g的产率得到Fmoc-5-氨基-3-氧杂戊酸
  参考文献：
  名称：

  强效低毒两性霉素 B 双酰胺衍生物的设计、合成和构效关系研究

  摘要：

  两性霉素 B (AMB, 1 ) 是治疗可能危及生命的侵袭性真菌感染 (IFI) 中最强大的抗生素，尽管源自自聚集的严重毒性极大地限制了其临床应用。在此，我们在 C16-COOH 和 C3'-NH 2上应用了双酰胺化策略，通过抑制自聚集来改善治疗特性。发现C16酰胺残基上的碱性氨基有利于活性，而亲脂性片段有助于降低毒性。此外， C3' 酰胺上的N-甲基氨基乙酰基和氨基乙酰基可以帮助保持抑菌效果。修改工作最终发现了36 (ED 50= 0.21 mg/kg)，其在小鼠中的抗真菌效力比其最佳衍生物安非酰胺强 1.5 倍，自聚集倾向低，因此急性毒性低。随着治疗指数的提高和良好的PK曲线，36有望作为第二代多烯类抗真菌剂进一步发展。

  DOI：

  10.1021/acs.jmedchem.1c02227

文献信息

• ANTI-EGFR ANTIBODY DRUG CONJUGATES
  申请人：AbbVie Inc.

  公开号：US20190153107A1

  公开（公告）日：2019-05-23

  The invention relates to anti-Epidermal Growth Factor Receptor (EGFR) antibody drug conjugates (ADCs) which inhibit Bcl-xL, including compositions and methods of using said ADCs.

  这项发明涉及抑制Bcl-xL的抗表皮生长因子受体（EGFR）抗体药物结合物（ADCs），包括使用所述ADCs的组合物和方法。
• [EN] ANTIBODY DRUG CONJUGATES WITH CELL PERMEABLE BCL-XL INHIBITORS<br/>[FR] CONJUGUÉS ANTICORPS MÉDICAMENTS AVEC DES INHIBITEURS BCL-XL À PERMÉABILITÉ CELLULAIRE
  申请人：ABBVIE INC

  公开号：WO2016094505A1

  公开（公告）日：2016-06-16

  Small molecule Bcl-xL inhibitors and Antibody Drug Conjugates (ADCs) comprising small molecule Bcl-xL inhibitors are disclosed herein. The Bcl-xL inhibitors and ADCs of the disclosure are useful for, among other things, inhibiting anti-apoptotic Bcl xL proteins as a therapeutic approach towards the treatment of diseases that involve a dysregulated apoptosis pathway.

  本文披露了小分子Bcl-xL抑制剂和包含小分子Bcl-xL抑制剂的抗体药物结合物（ADCs）。本公开的Bcl-xL抑制剂和ADCs可用于抑制抗凋亡Bcl-xL蛋白，作为治疗涉及失调凋亡途径的疾病的治疗方法之一。
• Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof
  申请人：Mjalli Adnan M. M.

  公开号：US20110201604A1

  公开（公告）日：2011-08-18

  Substituted fused imidazole derivatives, methods of their preparation, pharmaceutical compositions comprising a substituted fused imidazole derivative, and methods of use in treating inflammation are provided. The substituted fused imidazole derivatives may control the activity or the amount or both the activity and the amount of heme-oxygenase.

  提供了替代融合咪唑衍生物、其制备方法、包含替代融合咪唑衍生物的药物组合物，以及在治疗炎症中使用的方法。这些替代融合咪唑衍生物可能控制血红素氧合酶的活性或数量，或者同时控制活性和数量。
• [EN] ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES<br/>[FR] PEPTIDES INHIBITEURS PAR VOIE ORALE DU RÉCEPTEUR DE L'INTERLEUKINE-23 ET LEUR UTILISATION DANS LE TRAITEMENT DES MALADIES INFLAMMATOIRES DE L'INTESTIN
  申请人：PROTAGONIST THERAPEUTICS INC

  公开号：WO2016011208A1

  公开（公告）日：2016-01-21

  The present invention provides novel peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel disease. In a first aspect, the present invention provides a peptide inhibitor of an interleukin-23 receptor, or a pharmaceutically acceptable salt or solvate thereof, wherein the peptide inhibitor comprises an amino acid sequence of Formula (Xa). In another aspect, the present invention includes a pharmaceutical composition comprising a peptide inhibitor or a peptide dimer inhibitor of the present invention, and a pharmaceutically acceptable carrier.

  本发明提供了新型的干扰素-23受体肽抑制剂，以及相关的组合物和使用这些肽抑制剂来治疗或预防各种疾病和疾病的方法，包括炎症性肠病。在第一个方面，本发明提供了一种干扰素-23受体的肽抑制剂，或其药用盐或溶剂，其中该肽抑制剂包括式（Xa）的氨基酸序列。在另一个方面，本发明包括一种包含本发明的肽抑制剂或肽二聚体抑制剂的药物组合物，以及药用载体。
• ANTI-ALPHAVBETA1 INTEGRIN COMPOUNDS AND METHODS
  申请人：The Regents of the University of California

  公开号：US20160376266A1

  公开（公告）日：2016-12-29

  Provided herein, inter alia, are methods and compositions for inhibiting αvβ1 integrin and for treating fibrosis.

  本文提供了抑制αvβ1整合素和治疗纤维化的方法和组合物。